INTERVENTIONAL VASCULAR CORPORATE AND REGIONAL PRESS RELEASES

Please find below a list of our press releases.

5 Oct 2017

BTGplc acquires Roxwood Medical

London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.

21 Aug 2017

BTG and SIO expand Immuno-Oncology / Interventional Oncology grant programme

BTG plc (LSE: BTG), a global specialist healthcare company, and the Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, have expanded their commitment to the Immuno-Oncology / Interventional Oncology research grant programme, by announcing a second round of funding available to investigators.

5 Dec 2016

PneumRx® Coils included in new global clinical guidelines and given positive recommendation to treat severe emphysema patients in France

BTG plc (LSE: BTG), the global specialist healthcare company, today announces the inclusion of treatment with PneumRx® Coils in guidelines for the management of chronic obstructive pulmonary disease (COPD) published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

5 Dec 2016

Le Canada, premier pays à bénéficier d’une nouvelle option de traitement contre le cancer du foie

Les microsphères radio-opaques à élution médicamenteuse DC Bead LUMIMC offrent aux radiologistes interventionnels du Canada un traitement de nouvelle génération pour les patients atteints d’un cancer du foie

19 Oct 2016

First patient in Malaysia receives TheraSphere™ radioembolisation therapy

BTG plc (LSE: BTG), an international specialist healthcare company, today announced that the first patient in Malaysia was treated with TheraSphere™ – a transarterial radioembolisation (TARE) therapy, which targets primary liver cancer and metastatic colorectal cancer with a powerful dose of radiation while minimising exposure to healthy tissue.

14 Oct 2016

BTG and Mirada Medical announce CE Mark Certification for Simplicit90Y dosimetry software in Europe

New easy-to-use software designed to improve the planning of 90Y selective internal radiation therapy (SIRT) treatment for patients with liver cancer

BTG plc (LSE: BTG), an international specialist healthcare company, with Mirada Medical Ltd, a leading global brand in medical imaging software, today announced CE Mark certification for Simplicit90Y™ dosimetry software, designed to optimise the planning of 90Y selective internal radiation therapy (SIRT) and facilitate personalised treatment for patients with liver cancer. CE Mark certification follows approval for Simplicit90Y™ in Canada.

9 Sep 2016

BTG launches BETA™ Radiation Safety Programme, to reduce the risk of radiation exposure for healthcare professionals and patients

BTG plc (LSE: BTG), an international specialist healthcare company, today announced the launch of the BETA™ Radiation Safety Programme, a new initiative designed to reduce the risk of radiation exposure when performing selective internal radiation therapy (SIRT) with 90Y microspheres. Developed in collaboration with global experts, including Professor Jacob Kamen of the Mount Sinai Medical Center, the βETA™ Radiation Safety Programme analyses current practise and exposure risk, and provides recommendations to improve safety for healthcare professionals and patients.

2 Aug 2016

BTG announces successful CE Mark reclassification for DC Bead® to Class III based on its ability to administer medicines

BTG plc (LSE: BTG), a global specialist healthcare company, today announced that it has obtained European Conformity (CE) Mark from the Notified Body British Standards Institution (BSI) following completion of the reclassification of DC Bead® and DC BeadM1TM as Class III medical devices under Rule 8 of Annex IX to Directive 93/42/EEC.

15 Jun 2016

BTG completes the acquisition of Galil Medical

BTG completes the acquisition of Galil Medical

9 Jun 2016

BTG Joins Global Liver Institute Partnership Network to Transform Care for Liver Cancer Patients

BTG, a global leader in interventional oncology, announced today that it has joined the Global Liver Institute’s Partnership Network as a founding member.